Opening the door to the development of novel Abl kinase inhibitors
| Autor: | Renata Dalmaschio Daltoé, Pedro Alves Bezerra Morais, Heberth de Paula |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Pharmacology ABL Kinase Biology Ligand (biochemistry) medicine.disease Cell biology 03 medical and health sciences 030104 developmental biology Drug development Structural biology hemic and lymphatic diseases Drug Discovery Cancer cell medicine Molecular Medicine Kinase activity Chronic myelogenous leukemia |
| Zdroj: | Future medicinal chemistry. 8(17) |
| ISSN: | 1756-8927 |
| Popis: | The discovery of the importance of kinase activity and its relationship to the emergence and proliferation of cancer cells, due to changes in normal physiology, opened a remarkable pathway for the treatment of chronic myelogenous leukemia through intense search of drug candidates. Six Abl kinase inhibitors have received the US FDA approval as chronic myelogenous leukemia treatment, and continuous efforts in obtaining new, more effective and selective molecules are being carried out. Herein we discuss the mechanisms of Abl inhibition, structural features and ligand/protein interactions that are important for the design of new Abl kinase inhibitors. This review provides a broad overview of binding mode predictions, through molecular docking, which can be an approach to discover novel Abl kinase inhibitors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|